title: Influence of the vitreomacular interface on the efficacy of intravitreal therapy for uveitis-associated cystoid macular oedema.
abstract: OBJECTIVE
  To evaluate the effect of the vitreomacular interface (VMI) on treatment efficacy of intravitreal therapy in uveitic cystoid macular oedema (CME).
  
  
  METHODS
  Retrospective analysis of CME resolution, CME recurrence rate and monthly course of central retinal thickness (CRT), retinal volume (RV) and best corrected visual acuity (BCVA) after intravitreal injection with respect to the VMI configuration on spectral-domain OCT using chi-squared test and repeated measures anova adjusted for confounding covariates epiretinal membrane, administered drug and subretinal fluid.
  
  
  RESULTS
  Fifty-nine eyes of 53 patients (mean age: 47.4 ± 16.9 years) were included. VMI status had no effect on complete CME resolution rate (p = 0.16, corrected p-value: 0.32), time until resolution (p = 0.09, corrected p-value: 0.27) or CME relapse rate (p = 0.29, corrected p-value: 0.29). Change over time did not differ among the VMI configuration groups for BVCA (p = 0.82) and RV (p = 0.18), but CRT decrease was greater and faster in the posterior vitreous detachment (PVD) group compared to the posterior vitreous attachment (PVA) and vitreous macular adhesion (VMA) groups (p = 0.04). Also, the percentage of patients experiencing a ≥ 20% CRT thickness decrease after intravitreal injection was greater in the PVD group (83%) compared to the VMA (64%) and the PVA (16%) group (p = 0.027), however, not after correction for multiple testing (corrected p-value: 0.11).
  
  
  CONCLUSIONS
  The VMI configuration seems to be a factor contributing to treatment efficacy in uveitic CME in terms of CRT decrease, although BCVA outcome did not differ according to VMI status.
authors.affiliation: Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.|Department of Ophthalmology, Medical University Vienna, Vienna, Austria.|Department of Ophthalmology, Inselspital, University Hospital Bern, Bern, Switzerland.
authors.forename: Marion R
authors.initials: MR
authors.lastname: Munk
authors.affiliation: Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
authors.forename: Radha
authors.initials: R
authors.lastname: Ram
authors.affiliation: Biostatistics Collaboration Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
authors.forename: Alfred
authors.initials: A
authors.lastname: Rademaker
authors.affiliation: Biostatistics Collaboration Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
authors.forename: Dachao
authors.initials: D
authors.lastname: Liu
authors.affiliation: Department of Ophthalmology, University of Illinois, Eye and Ear Infirmary, Chicago, IL, USA.
authors.forename: Vikram
authors.initials: V
authors.lastname: Setlur
authors.affiliation: Department of Ophthalmology, University of Illinois, Eye and Ear Infirmary, Chicago, IL, USA.
authors.forename: Felix
authors.initials: F
authors.lastname: Chau
authors.affiliation: Department of Ophthalmology, Medical University Vienna, Vienna, Austria.
authors.forename: Ursula
authors.initials: U
authors.lastname: Schmidt-Erfurth
authors.affiliation: Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
authors.forename: Debra A
authors.initials: DA
authors.lastname: Goldstein
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004343:Drug Implants; D005128:Eye Diseases / Q000503:physiopathology*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012164:Retinal Diseases / Q000503:physiopathology*; D012189:Retrospective Studies; D000267:Tissue Adhesions / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000627:therapeutic use; D014605:Uveitis / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D004343:Drug Implants; D005938:Glucocorticoids; D000068258:Bevacizumab; D003907:Dexamethasone; D014222:Triamcinolone Acetonide
keywords: cystoid macular oedema; intravitreal therapy; macular oedema; optical coherence tomography; posterior vitreous attachment; triamcinolone; uveitis; vitreomacular adhesion; vitreomacular traction